Recruiting Underway in FSD Pharma's Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
Stock Information for FSD Pharma Inc.
Loading
Please wait while we load your information from QuoteMedia.